Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cholecystectomy & appendectomy cases in Massachusetts: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 85 | 3,826 | 28% |
| 2020 | 67 | 3,190 | 30% |
| 2021 | 79 | 3,436 | 32% |
| 2022 | 64 | 3,160 | 35% |
| 2023 | 57 | 3,162 | 38% |
| 2024 | 60 | 3,162 | 39% |
| 2025 from claims | – | 3,210 2,946–3,396 | 40% |
| 2026 forecast | – | 3,308 2,910–3,817 | 39% |
| 2027 forecast | – | 3,359 2,872–4,003 | 40% |
| 2028 forecast | – | 3,412 2,847–4,178 | 40% |
| 2029 forecast | – | 3,465 2,830–4,346 | 40% |
| 2030 forecast | – | 3,519 2,819–4,510 | 40% |
The highest-volume laparoscopic cases; identifies every active general surgeon. Professional codes (what the surgeon bills): CPT 47562, 47563, 44970, 47600; the hospital bills MS-DRG 417, 418, 419, 338, 339, 340, 397, 398, 399.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 25% of the cases CMS names in Massachusetts; 44 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 49% inpatient hospital, 51% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~3,300 | ~1,600 | ~1,700 |
| 2027 · ~3,400 | ~1,700 | ~1,700 |
| 2028 · ~3,400 | ~1,700 | ~1,700 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 50% (49% in 2025), hospital outpatient about 50% (51% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 96 | 5,762−3.7%/yr | −3.7%/yr | 3.3 | 2% | 6,020 in 2030+0.7%/yr |
| Pennsylvania | 95 | 5,634−4%/yr | −4%/yr | 4.3 | 1% | 5,840 in 2030+0.6%/yr |
| New Jersey | 81 | 3,400−3.2%/yr | −3.2%/yr | 3.3 | 1% | 3,540 in 2030+0.7%/yr |
| Connecticut | 13 | 1,125−6.5%/yr | −6.5%/yr | 3.5 | 0% | 1,160 in 2030+0.5%/yr |
| New Hampshire | 6 | 766−3%/yr | −3%/yr | 3.4 | 2% | 990 in 2030+4.4%/yr |
| Maine | 3 | 578−9.6%/yr | −9.6%/yr | 3.8 | 0% | 630 in 2030+1.4%/yr |
| Rhode Island | 4 | 359−3.4%/yr | −3.4%/yr | 4.1 | 0% | 360 in 2030−0.1%/yr |
| Vermont | 2 | 272−7%/yr | −7%/yr | 2.4 | 0% | 430 in 2030+8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 66 | 5,037−2.7%/yr | −2.7%/yr | 5.60.9× | 1% | 5,860 in 2030+2.6%/yr |
| Colorectal resection | 10 | 1,485−3.1%/yr | −3.1%/yr | 1.61.0× | 0% | 1,660 in 2030+1.9%/yr |
| Antireflux & hiatal hernia surgery | 8 | 640+1.2%/yr | +1.2%/yr | 0.71.1× | 0% | 1,240 in 2030+12%/yr |
| Breast reconstruction | 1 | 327−2.7%/yr | −2.7%/yr | 0.30.8× | 0% | 340 in 2030+0.7%/yr |
| Bariatric surgery | 0 | 230−14%/yr | −14%/yr | 0.21.4× | 0% | 190 in 2030−2.8%/yr |
Cholecystectomy & appendectomy in every state, and its device makers · Every procedure market in Massachusetts · Every state · Compare with New York
Applied Medical Resources leads with 46% of company spending on these surgeons in 2025, +1 pts on 2024.
In 2025, 10 companies reported engagement with Massachusetts’s surgeons worth $71K in consulting, speaking, meals and travel tied to these products, about $1,179 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 33 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.